Biologic pharmaceuticals are complex, high-cost therapeutics used to treat severe and chronic conditions. 1 Biosimilar biological products can increase access to therapy and lower health care costs. The development and approval of biosimilar biologics in the United States was made possible by the Biologics Price Competition and Innovation Act passed in 2010. As of June 1, 2018, 10 biosimilars had been approved by the US Food and Drug Administration (FDA) . 2 This study evaluated uptake of the first approved biosimilar biologic, filgrastim-sndz (Zarxio), relative to its originator filgrastim product (Neupogen). These products share multiple indications for neutropenia and malignancy. Tbo-filgrastim (Granix), a stand-alone alternative biologic with a single indication, was also evaluated.
Methods | All filgrastim administrations of any dose between January 1, 2014, and December 31, 2016, in Medicare Part B claims were identified using Healthcare Common Procedure Coding System billing codes. Beneficiaries were enrolled in Medicare fee for service from at least 6 months before to at least 10 days after administration. Cohorts were defined by the filgrastim product administered; beneficiaries were included in multiple cohorts if they received multiple products during the study period. Beneficiary demographics and prevalence of indicated conditions were evaluated. This descriptive study was approved as an FDA surveillance activity by the FDA Center for Drug Evaluation and Research institutional review board liaison. Least squares regression was used to depict the utilization trend. A standardized mean difference threshold of 0.1 was used to highlight larger differences between cohort characteristics. Analyses were performed using SAS, version 9.4 (SAS Institute Inc).
Results | Monthly administrations of any filgrastim product decreased by 13%, from 28 520 in January 2014 to 24 898 in December 2016 (Figure, A) . Monthly administrations of filgrastimsndz increased to 32% of all filgrastim use and tbo-filgrastim increased to 16%, while the originator filgrastim product declined from 97% to 52% (Figure, B) . Initial uptake of filgrastimsndz was rapid, with monthly use surpassing tbo-filgrastim in March 2016. Beneficiaries who received filgrastim-sndz were on average slightly older. Product choice also differed by geographic region and original Medicare enrollment status (Table) . Among beneficiaries who received filgrastim-sndz, 22% had previously received the originator filgrastim and 73% were new users.
The prevalence of indications was similar across all products despite tbo-filgrastim's single indication for patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. This indication was associated with 70% to 73% of claims across all products.
Discussion | Substantial uptake of alternative filgrastim products occurred in 2014-2016, including among beneficiaries previously receiving the originator product. The more rapid uptake of filgrastim-sndz over the stand-alone biologic does not appear to be driven by the products' list prices, as the tbo-filgrastim discount from the originator product was similar to or higher than 3 the initial discount of 15% for filgrastim-sndz. 4 The use of tbo-filgrastim beyond its labeled indication may result from clinicians' familiarity with product use outside the US approval system, accepted practices, product availability, or other factors. Although biosimilar uptake rates in the United States mirror the experience of some European Union countries, 5 the decline in filgrastim use differs from the increase in the United Kingdom.
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Although this study looked at filgrastim administrations billed only through Medicare Part B, a small percentage of overall filgrastim claims are billed through Part D instead. Additionally, presence of indications was identified with claims data definitions; no medical record confirmation was available. Data on filgrastim utilization can inform future research and policy as the number of approved biosimilar products increases.
